JP2014530001A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530001A5
JP2014530001A5 JP2014531755A JP2014531755A JP2014530001A5 JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5 JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014531755 A JP2014531755 A JP 2014531755A JP 2014530001 A5 JP2014530001 A5 JP 2014530001A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
tnf
light chain
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014531755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530001A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530001A publication Critical patent/JP2014530001A/ja
Publication of JP2014530001A5 publication Critical patent/JP2014530001A5/ja
Pending legal-status Critical Current

Links

JP2014531755A 2011-09-23 2012-09-19 抗腫瘍壊死因子−α剤及びその使用 Pending JP2014530001A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538548P 2011-09-23 2011-09-23
US61/538,548 2011-09-23

Publications (2)

Publication Number Publication Date
JP2014530001A JP2014530001A (ja) 2014-11-17
JP2014530001A5 true JP2014530001A5 (enExample) 2015-11-12

Family

ID=47146619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531755A Pending JP2014530001A (ja) 2011-09-23 2012-09-19 抗腫瘍壊死因子−α剤及びその使用

Country Status (9)

Country Link
US (2) US9399678B2 (enExample)
EP (1) EP2758434A2 (enExample)
JP (1) JP2014530001A (enExample)
CN (1) CN103906765A (enExample)
AU (1) AU2012310328A1 (enExample)
BR (1) BR112014006929A2 (enExample)
CA (1) CA2849409A1 (enExample)
SG (2) SG11201400879SA (enExample)
WO (1) WO2013043070A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
EP3247407A4 (en) * 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
WO2016144978A1 (en) * 2015-03-09 2016-09-15 Oxeia Biopharmaceuticals, Inc. Methods of treating cognitive impairments or dysfunction
AU2017214685B2 (en) * 2016-02-05 2024-03-07 The Board Of Regents Of The University Of Texas System EGFL6 specific monoclonal antibodies and methods of their use
WO2018176089A1 (en) * 2017-03-27 2018-10-04 Garvan Institute Of Medical Research Screening methods
CN111164104A (zh) 2017-08-09 2020-05-15 麻省理工学院 白蛋白结合肽缀合物及其方法
CN111699003B (zh) * 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
CN110066337B (zh) * 2019-05-16 2022-06-21 艾柏森(江苏)生物科技有限公司 一种抗TNF-α抗体
CA3194403A1 (en) * 2020-10-01 2022-04-07 Steven Josephs Reduced leaching of a ligand
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
CN114621354A (zh) * 2020-12-11 2022-06-14 正大天晴药业集团股份有限公司 Fab-白蛋白结合肽融合蛋白及其制备方法和应用
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
SE9002213D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Albumin binding proteins
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
EP0517930B1 (en) 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993023434A2 (en) 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US6962686B2 (en) 1994-10-12 2005-11-08 California Institute Of Technology Cell-specific gene delivery vehicles
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6373577B1 (en) 1998-05-20 2002-04-16 Graffinity Pharmaceutical Design Gmbh Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
US6311415B1 (en) 1998-09-14 2001-11-06 Lind Shoe Company Bowling shoe with replaceable tip
US6319691B1 (en) 1999-06-15 2001-11-20 Usa Universe Bioengineering, Inc. Fusion proteins comprising IFN-alpha2b and TM-alpha1
US7608681B2 (en) 1999-12-24 2009-10-27 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
CN1678634A (zh) * 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
US8642743B2 (en) 2004-04-06 2014-02-04 Affibody Ab Method for reducing the immune response to a biologically active protein
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
NZ569988A (en) 2006-02-01 2011-09-30 Cephalon Australia Pty Ltd Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
US20110319597A1 (en) * 2008-08-14 2011-12-29 Caphalon Australia Pty. Ltd. Variant domain antibodies
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
US20110194996A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Transport container for stabilized liquid samples
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
AU2012310328A1 (en) * 2011-09-23 2014-04-10 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Anti-Tumor Necrosis Factor-alpha agents and uses thereof

Similar Documents

Publication Publication Date Title
US20240392002A1 (en) Anti-ror antibody constructs
KR102482710B1 (ko) 항-pd-1 항체, 이의 생산 방법 및 사용 방법
JP7373650B2 (ja) 抗pd-l1シングルドメイン抗体
JP2013523184A5 (enExample)
JP2010535012A5 (enExample)
JP2010526028A5 (enExample)
IL280467B1 (en) Antibody constructs for cldn18.2 and cd3
JP2021524268A5 (enExample)
JP2021525546A5 (enExample)
JP2019522490A5 (enExample)
JP2018502050A5 (enExample)
JP2012515540A5 (enExample)
JP2016507523A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2018503380A5 (enExample)
JP2012518425A5 (enExample)
JP2010533498A5 (enExample)
AU2015328090A1 (en) Humanized anti-OX40 antibodies and uses thereof
JP2014503189A5 (enExample)
US12590149B2 (en) Antibody and bispecific antibody targeting LAG-3 and use thereof
TW201716441A (zh) Egfrviii及cd3抗體構築體
JP2012525829A5 (enExample)
HRP20250195T1 (hr) Anti-fcrn antitijela
JP2018510617A5 (enExample)
RU2010129045A (ru) Связывающие молекулы к рецептору ох40 человека